Skip to main content

Table 1 Reported complications with COVID-19

From: ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review

 Total number of patientsVenovenous ECMO %Pulmonary complicationsCardiovascular complicationsOther complications
Huang C [27]41 hospitalisedNAARDS (29%)Acute cardiac injury (12%)a
Shock (7%)
AKI (7%)
Secondary infection (10%)
Wang D [28]138 hospitalisedNAARDS (19.6%)Shock (8.7%), Acute cardiac injury (7.2%), Arrhythmia (16.7%)AKI (3.6%)
Yang X [29]52 ICU admittedNAARDS (67%)
Hospital acquired pneumonia (11.5%)
Pneumothorax (2%)
Cardiac injury (23%)AKI (29%)
Liver dysfunction (29%)
Hyperglycaemia (35%)
GI haemorrhage (4%)
Bacteremia (2%)
Urinary tract infection (2%)
Zhou F [30]191 hospitalisedNARespiratory failure (54%)
ARDS (31%)
Heart failure (23%)
Acute cardiac injury (17%)
Septic shock (20%)
Sepsis (59%)
Coagulopathy (19%)
Acute kidney injury (15%)
Secondary infection (15%)
Hypoproteinemia (12%)
Acidosis (9%)
Varga Z [32]3 casesNo ECMORespiratory failure (3)Endothelitis in organ vessels (3)
Myocardial infarction (1)
Reduced LV EF and circulatory collapse (1)
Mesenteric ischemia (2)
Multiorgan failure (1)
Xie Y [31]2 casesNo ECMOPulmonary embolism (2)  
Hua A [33]1 caseNo ECMO Myopericarditis (1)
Cardiac tamponade
Pericardial effusion
 
Inciardi RM [34]1 caseNo ECMO Myopericarditis with systolic dysfunction (1) 
  1. AKI acute kidney injury, ARDS acute respiratory distress syndrome, ECMO extracorporeal membrane oxygenation, GI gastrointestinal, NA not applicable
  2. aDefined as blood levels of hypersensitive troponin I above the 99th percentile upper reference limit (> 28 pg/mL) or new abnormalities shown on electrocardiography and echocardiography